FOXO4-DRI 10mg
FOXO4-DRI is an investigational D-retro-inverso peptide researched as a senolytic targeting p53 interactions in non-viable cells.
Mechanism
Competitively inhibits the FOXO4-p53 complex at the p53 TAD2 interface, freeing p53 to selectively trigger apoptotic cell death within senescent cellular populations.
Dosing
Standard laboratory protocols report an initial starting level of 250 mcg administered once daily.
Reconstitution
Reconstituting a 10 mg vial with 3.0 mL of bacteriostatic water achieves an approximate working concentration of 3.33 mg/mL (33.3 mcg per U-100 syringe unit).
Storage
Maintain lyophilized powder in cold storage at -20 °C, and keep the reconstituted solution refrigerated between 2 °C and 8 °C without refreezing.
Mix & measure FOXO4-DRI 10mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure FOXO4-DRI 10mg
Vial strength → BAC water → target dose
Total doses in vial: 40.0
U-100 syringe: 100 units = 1 mL
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Weeks 1–4 | 250 mcg (1× daily) | 7.5 units (0.075 mL) |
| Weeks 5–8 | 375 mcg (1× daily) | ~11 units (0.11 mL) |
| Weeks 9–12 | 500 mcg (1× daily) | 15 units (0.15 mL) |
| Weeks 13–16 | 500 mcg (1× daily) | 15 units (0.15 mL) |
Reconstitution Steps
- 1
Draw 3.0 mL of bacteriostatic water into a sterile mixing syringe.
- 2
Slowly introduce the diluent against the internal glass surface of the vial to prevent foaming.
- 3
Gently roll or swirl the vial until the lyophilized cake is fully dissolved without vigorous agitation.
- 4
Record the date and preparation concentration on the vial label and place it immediately into refrigerated storage at 2–8 °C away from light.
Supplies Needed
Peptide Vial
Contains 10 mg of lyophilized FOXO4-DRI research peptide
Insulin Syringes (U-100)
Used for precise measurement and subcutaneous administration of microgram-range volumes
Bacteriostatic Water
Supplies sterile diluent containing benzyl alcohol for reconstitution
Alcohol Swabs
Ensures antiseptic handling of vial septums and target research injection sites
Why researchers study it
Senolytic clearing of senescent cells
Tissue homeostasis and functional restoration in animal models
Chemotherapy-induced cellular aging pathways
FOXO4-p53 molecular binding and apoptosis mechanisms
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
FOXO4-DRI, alternatively identified in preclinical literature as Proxofim, is an engineered D-retro-inverso peptide derived from the FOXO4 transcription factor sequence. Its synthetic design incorporates modified stereochemistry that grants resistance to enzymatic degradation, permitting extended stability within biological systems. The molecule has garnered significant scientific attention within anti-aging and senolytic research as a targeted pathway disruptor. Preclinical animal models indicate that FOXO4-DRI works by interfering with the intracellular binding between FOXO4 and the tumor suppressor protein p53. In senescent cells, this disruption releases p53 into the cytoplasm to initiate targeted apoptosis without damaging adjacent healthy, non-senescent tissues. Animal studies have observed improvements in physical performance, renal function markers, and coat density after senescent cell clearance. All existing investigations regarding FOXO4-DRI remain strictly confined to cellular assays and rodent models. It is an unapproved, experimental peptide without established clinical safety, toxicity profiles, or validated human pharmacokinetics, remaining solely designated for controlled laboratory experimentation.
References
- 1.Baar et al., Cell, 2017 — Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging
- 2.Zhang et al., Journal of Cellular and Molecular Medicine, 2020 — FOXO4 peptide targets myofibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice
- 3.Wang et al., Aging (Albany NY), 2020 — FOXO4-DRI alleviates age-related testosterone insufficiency by targeting senescent Leydig cells in aged mice
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allGHRP-2 10mg
A synthetic hexapeptide ghrelin receptor agonist investigated for eliciting pulsatile growth hormone and IGF-1 secretion.
View ProtocolSLU-PP-332 5mg
Preclinical synthetic pan-ERR agonist studied as an exercise mimetic for mitochondrial oxidation and metabolic regulation.
View ProtocolEcnoglutide 10mg
A novel cAMP-biased, long-acting GLP-1 receptor agonist studied for glycemic management and weight reduction.
View Protocol